Guidelines
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2020; 26(45): 7088-7103
Published online Dec 7, 2020. doi: 10.3748/wjg.v26.i45.7088
Chinese guidelines on the management of liver cirrhosis (abbreviated version)
Xiao-Yuan Xu, Hui-Guo Ding, Wen-Gang Li, Jing-Hang Xu, Ying Han, Ji-Dong Jia, Lai Wei, Zhong-Ping Duan, En-Qiang Ling-Hu, Hui Zhuang
Xiao-Yuan Xu, Jing-Hang Xu, Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
Hui-Guo Ding, Hepatology and Digestion Center, Beijing You-An Hospital, Capital Medical University, Beijing 100069, China
Wen-Gang Li, Department of Liver Oncology, Cancer Radiation Therapy Center, Fifth Medical Center, PLA General Hospital, Beijing 100039, China
Ying Han, Department of Immunology and Liver Diseases, Beijing You-An Hospital, Capital Medical University, Beijing 100069, China
Ji-Dong Jia, Hepatology Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Lai Wei, Internal Medicine of Hepatopancreatobiliary, Beijing Tsinghua Changgung Hospital, Beijing 102218, China
Zhong-Ping Duan, Artificial Liver Center, Beijing You-An Hospital, Capital Medical University, Beijing 100069, China
En-Qiang Ling-Hu, Department of Gastroenterology, First Medical Center, PLA General Hospital, Beijing 100853, China
Hui Zhuang, Department of Pathogenic Biology, Peking University Health Science Center, Beijing 100191, China
Author contributions: Xu XY edited and reviewed the manuscript; Ding HG, Li WG, Xu JH, Han Y, Jia JD, Wei L, Duan ZP, Ling-Hu EQ, and Zhuang H approved the final article.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yuan Xu, MD, Doctor, Department of Infectious Diseases, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. xiaoyuanxu6@163.com
Received: April 20, 2020
Peer-review started: April 20, 2020
First decision: May 26, 2020
Revised: June 3, 2020
Accepted: November 12, 2020
Article in press: November 12, 2020
Published online: December 7, 2020
Abstract

Based on reviews of the literature and experts’ consensus, the Chinese Society of Hepatology developed guidelines for the diagnosis and treatment of liver cirrhosis, in order to improve clinical practice. In addition to what has been covered in previously published guidelines on the management of cirrhosis complications, these guidelines add new sections and provide updates. The guidelines emphasize the early diagnosis of the cause and assessment of complications. Comprehensive treatments including etiological treatment and complication management should be initiated immediately. In addition, regular monitoring, especially surveillance of hepatocellular carcinoma, is crucial for managing patients.

Keywords: Liver cirrhosis, Diagnosis, Therapy, Guidelines, Hypertension portal, Recompensated stage

Core Tip: Based on reviews of the literature and experts’ consensus, the Chinese Society of Hepatology developed guidelines for the diagnosis and treatment of liver cirrhosis, in order to improve clinical practice. In addition to what has been covered in previously published guidelines on the management of cirrhosis complications, the guidelines adds new sections and provides updates. The guidelines emphasizes the early diagnosis of the cause and assessment of complications. Comprehensive treatment including etiological treatment and complication management should be initiated immediately. In addition, regular monitoring, especially surveillance of hepatocellular carcinoma, is crucial to manage patients.